NCT03283267View on ClinicalTrials.gov

A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 24, 2017

Primary Completion Date

November 23, 2017

Study Completion Date

November 23, 2017

Conditions
Hyperkalemia
Interventions
DRUG

Sodium Zirconium Cyclosilicate (ZS)

Sodium zirconium cyclosilicate (ZS) is a non-absorbed, inorganic crystalline compound that selectively captures potassium ions in exchange for sodium and hydrogen ions in the gastrointestinal tract after oral administration.

Trial Locations (1)

Unknown

Research Site, Hong Kong

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY